A tailored mRNA cancer vaccine shows promise in cutting melanoma recurrence risk by 12 percentage points. Experts predict US and UK approval in 2025, but cost concerns loom.
By Adam Makins·
A groundbreaking personalized mRNA vaccine for melanoma is poised to transform how we treat the deadliest form of skin cancer. Expected to gain approval in the US, Europe, and the UK next year, this innovative approach harnesses the power of genetic sequencing to create bespoke cancer treatments tailored to individual patients.
The vaccine works by analyzing a patient’s unique tumor mutations and instructing immune cells to recognize and attack those specific cancer cells. In late-stage trials involving over 1,100 patients with high-risk melanoma, the vaccine combined with standard immunotherapy delivered impressive results: 82 percent of recipients remained cancer-free after two years, compared to 70 percent receiving immunotherapy alone.
The process begins with genetic sequencing of a small tumor sample, which is then compared against healthy blood cells. Researchers identify mutations present only in the cancer. Using the same mRNA technology that powered COVID-19 vaccines, the treatment encodes up to 34 of these mutations into therapeutic molecules.
When administered alongside pembrolizumab, a checkpoint inhibitor that prevents immune exhaustion, the vaccine essentially provides immune cells with a detailed “fingerprint” of the cancer. This dual approach means T-cells can hunt down tumor cells more effectively while maintaining their attack capacity over time.
“It’s a really exciting result,” says Rebecca Lee from the University of Manchester. “This helps T-cells recognize the cancer better, and then pembrolizumab prevents those T-cells from becoming exhausted once they’ve started attacking the cancer cells.”
With 19,400 melanoma cases diagnosed annually in the UK alone, and about 25 percent classified as high-risk, thousands of patients could potentially benefit from this treatment. The trial’s side effect profile matched the control group, suggesting the vaccine is well-tolerated.
Despite the clinical promise, significant hurdles remain. Manufacturing personalized vaccines is extraordinarily expensive. Reuters reported in January that costs could reach around $200,000 per treatment, raising serious questions about accessibility through the UK’s National Health Service.
“If it was a cheap drug, I’d definitely say it will get approved for NHS use, but it’s going to be expensive,” Lee explains. Neither Moderna nor Merck, the companies behind the vaccine, have publicly confirmed pricing, leaving uncertainty about affordability and widespread implementation.
This cost barrier reflects a broader science challenge: cutting-edge personalized medicine often comes with cutting-edge price tags. The question becomes whether healthcare systems can justify the investment when traditional treatments remain significantly cheaper.
While the two-year data is encouraging, researchers haven’t yet tracked whether the vaccine actually improves long-term survival rates. That evidence should emerge within a few years. Alan Melcher from the Institute of Cancer Research notes that combining cancer recurrence and death into one metric means we’re primarily seeing evidence of reduced recurrence rather than proven survival benefits.
Further research could also identify which patients are most likely to benefit. Some mutations may fail to trigger protective immunity, or pembrolizumab alone might already achieve optimal results for certain individuals. Blood or tumor biomarkers could eventually predict responders, making treatment more targeted and cost-effective.
The potential extends well beyond melanoma. James Larkin, also at the Institute of Cancer Research, suggests personalized vaccines could work against lung, bladder, and kidney cancers, which are routinely treated with immunotherapy.
This represents a fundamental shift in how we approach health treatment, moving away from one-size-fits-all solutions toward precision medicine tailored to individual genetic profiles. As technology advances and manufacturing scales up, costs may eventually decline, making these treatments accessible to broader patient populations.
The approval process next year will mark a pivotal moment in cancer treatment history, but the real test will be whether healthcare systems can afford to deliver this promise to patients who need it most.
Source: New Scientist
